Research graph
References from Clinical outcomes of teduglutide therapy in children with short bowel syndrome–associated intestinal failure: A single-center experience. Local targets link to admitted publications; unresolved targets remain external evidence.
ASPEN definitions in pedistric intestinal failure.JPEN
10.1002/jpen.2232 · 2022 · External reference
Short Bowel Syndrome as the Leading Cause of Intestinal Failure in Early Life: Some Insights into the Management
10.5223/pghn.2019.22.4.303 · 2019 · External reference
Short bowel syndrome and intestinal failure: consensus definitions and overview
10.1016/j.cgh.2005.10.002 · 2006 · External reference
Redefining short bowel syndrome in the 21st century
10.1038/pr.2016.265 · 2017 · External reference
Clinical significance of GLP-2 in short-bowel syndrome
10.1093/jn/133.11.3721 · 2003 · External reference
Improved survival in a multidisciplinary short bowel syndrome program
10.1016/j.jpedsurg.2007.09.014 · 2008 · External reference
Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes
10.1067/mpd.2001.114481 · 2001 · External reference
Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience
10.1016/j.jpeds.2004.02.030 · 2004 · External reference
Use of glucagon-like polypeptide 2 analogs for intestinal failure
10.1080/14656566.2024.2431291 · 2024 · External reference
Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome
10.1016/j.jpeds.2016.10.027 · 2017 · External reference
Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: a 24-week, phase III study
10.1002/jpen.1690 · 2020 · External reference
Safety findings in pediatric patients during long-term treatment with teduglutide for short bowel syndrome–associated intestinal failure: pooled analysis of 4 clinical studies
10.1002/jpen.2061 · 2021 · External reference
Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure
10.1002/jpn3.12276 · 2024 · External reference
2000 CDC Growth Charts for the United States: methods and development
2002 · External reference
Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data
10.1097/mpg.0000000000002899 · 2020 · External reference
The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience
10.1097/mpg.0000000000003541 · 2022 · External reference
Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome
10.1016/j.ajcnut.2023.02.019 · 2023 · External reference
The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
10.3389/fphar.2024.1439781 · 2024 · External reference
Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series
10.1016/j.clnu.2019.08.020 · 2020 · External reference
Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure
10.1016/j.cgh.2012.12.029 · 2013 · External reference
Teduglutide for the treatment of short bowel syndrome: a double-edged sword?
10.1016/j.ajcnut.2023.04.009 · 2023 · External reference
